CLOs on the Move

Luzsana Biotechnology

www.luzsana.com

 
Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.luzsana.com
  • 400 Alexander Park Drive
    Princeton, NJ USA 08540
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

ADMA Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...

Premiera Care Communities

Premiera Care Communities is a Oakdale, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cambrian Innovation

Spun out of MIT in 2006, Cambrian Innovation is commercializing a portfolio of environmental solutions based on newly discovered electrically active microbes. By harnessing the power of bio-electricity and advances in electrochemistry, Cambrian Innovation`s products help industrial, agricultural, and government customers save money while recovering clean water and clean energy from wastewater streams. Our bio-electrogenic sensor platform enables low-cost, real-time monitoring of critical natural resources. At Cambrian Innovation our vision is simple: Industry is an ecosystem. Because the biological world is by definition sustainable, creative application of biological engineering is the best way to solve our most pressing environmental challenges. Cambrian Innovation`s solutions leverage advances in bio-electricity to help industrial and agricultural customers cut costs while meeting their environmental goals.

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.